Charalambos (Babis) Andreadis, MD, MSCE


Associate Professor of Clinical Medicine, Department of Medicine, UCSF

Phone: (415) 353-2421 (appts)
Box 0324, UCSF
San Francisco, CA 94143-0324

View on UCSF Profiles

Additional Websites


Oberlin College, Oberlin, OH, BA, 1993, Cum Laude, Biochemistry
College of Physicians & Surgeons, Columbia University, New York, NY, MD, 1998, Medicine
University of Pennsylvania, Philadelphia, PA, MSCE, 2005, Pharmacogenetics/Epidemiology

Professional Experience

  • 1998 - 2001
    Columbia-Presbyterian Medical Center (New York, NY), Resident, Department of Internal Medicine
  • 2001 - 2004
    Hospital of the University of Pennsylvania (Philadelphia, PA), Fellow, Division of Hematology/Oncology
  • 2004 - 2005
    University of Pennsylvania (Philadelphia, PA), Research Associate, Division of Hematology/Oncology
  • 2005 - 2006
    University of Pennsylvania (Philadelphia, PA), Clinical Instructor, Division of Hematology/Oncology
  • 2006 - 2008
    University of Pennsylvania (Philadelphia, PA), Assistant Professor, CE, Division of Hematology/Oncology
  • 2006 - 2008
    University of Pennsylvania (Philadelphia, PA), Associate Scholar, Center for Clinical Epidemiology and Biostatistics
  • 2008 - 2013
    Assistant Professor of Clinical Medicine, UCSF
  • 2013 - present
    Associate Professor of Clinical Medicine, UCSF

Honors & Awards

  • 1992
    Phi Beta Kappa, Z of Ohio
  • 1993
    Departmental honors and Cum Laude, Oberlin College
  • 1994 - 1998
    Nicholplus Interschool Fellowship, Columbia University
  • 1995
    McGraw-Hill Publishers Award, Columbia University
  • 1996
    Grove memorial Scholarship, Columbia University
  • 1997
    Alpha Omega Alpha, A of New York
  • 1998
    The Endocrine Society Medical Student Achievement Award
  • 2004
    Pharmacoepidemiology Training Award, University of Pennsylvania

Selected Publications

  1. Gupta NK, Andreadis C. New Meets Old: A Case Study and Review of Novel Therapeutics for the Treatment of CLL in Older Patients. J Natl Compr Canc Netw. 2014 Oct; 12(10):1371-5.
    View on PubMed
  2. Keller JW, Andreadis C, Damon LE, Kaplan LD, Martin TG, Wolf JL, Ai WZ, Venstrom JM, Smith CC, Gaensler KM, Hwang J, Olin RL. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients. J Geriatr Oncol. 2014 Jul; 5(3):238-44.
    View on PubMed
  3. Olin RL, Andreadis C. David versus Goliath: decision analysis predicts results of a large clinical trial in follicular lymphoma. J Clin Oncol. 2013 Oct 1; 31(28):3608-9.
    View on PubMed
  4. Yee SW, Mefford JA, Singh N, Percival ME, Stecula A, Yang K, Witte JS, Takahashi A, Kubo M, Matsuda K, Giacomini KM, Andreadis C. Impact of polymorphisms in drug pathway genes on disease-free survival in adults with acute myeloid leukemia. J Hum Genet. 2013 Jun; 58(6):353-61.
    View on PubMed
  5. Olin RL, Kanetsky PA, Ten Have TR, Nasta SD, Schuster SJ, Andreadis C. Determinants of the optimal first-line therapy for follicular lymphoma: a decision analysis. Am J Hematol. 2010 Apr; 85(4):255-60.
    View on PubMed
  6. Pincus LB, Zehnder JL, Neuhaus IM, Andreadis C, McCalmont TH. Presentation of extranodal natural killer T-cell lymphoma, nasal type, with poorly circumscribed erythematous patches. J Clin Oncol. 2010 Feb 20; 28(6):e94-5.
    View on PubMed
  7. Tsai DE, Luger SM, Andreadis C, Vogl DT, Kemner A, Potuzak M, Goradia A, Loren AW, Perl AE, Schuster SJ, Porter DL, Stadtmauer EA, Goldstein SC, Thompson JE, Swider C, Bagg A, Mato AR, Carroll M. A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia. Clin Cancer Res. 2008 Sep 1; 14(17):5619-25.
    View on PubMed
  8. Vogl DT, Liu SV, Chong EA, Luger SM, Porter DL, Schuster SJ, Tsai DE, Perl A, Loren AW, Goldstein SC, Nasta SD, Andreadis C, Mangan PA, Hummel K, Siegel DL, Glatstein E, Stadtmauer EA. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support. Am J Hematol. 2007 Dec; 82(12):1071-5.
    View on PubMed
  9. Mato AR, Morgans AK, Roullet MR, Bagg A, Glatstein E, Litt HI, Downs LH, Chong EA, Olson ER, Andreadis C, Schuster SJ. Primary cardiac lymphoma: utility of multimodality imaging in diagnosis and management. Cancer Biol Ther. 2007 Dec; 6(12):1867-70.
    View on PubMed
  10. Ahya VN, Douglas LP, Andreadis C, Arnoldi S, Svoboda J, Kotloff RM, Hadjiliadis D, Sager JS, Woo YJ, Pochettino A, Schuster SJ, Stadtmauer EA, Tsai DE. Association between elevated whole blood Epstein-Barr virus (EBV)-encoded RNA EBV polymerase chain reaction and reduced incidence of acute lung allograft rejection. J Heart Lung Transplant. 2007 Aug; 26(8):839-44.
    View on PubMed
  11. Andreadis C, Gimotty PA, Wahl P, Hammond R, Houldsworth J, Schuster SJ, Rebbeck TR. Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma. Blood. 2007 Apr 15; 109(8):3409-16.
    View on PubMed
  12. Frey NV, Svoboda J, Andreadis C, Tsai DE, Schuster SJ, Elstrom R, Rubin SC, Nasta SD. Primary lymphomas of the cervix and uterus: the University of Pennsylvania's experience and a review of the literature. Leuk Lymphoma. 2006 Sep; 47(9):1894-901.
    View on PubMed
  13. Fuster D, Chiang S, Andreadis C, Guan L, Zhuang H, Schuster S, Alavi A. Can [18F]fluorodeoxyglucose positron emission tomography imaging complement biopsy results from the iliac crest for the detection of bone marrow involvement in patients with malignant lymphoma? Nucl Med Commun. 2006 Jan; 27(1):11-5.
    View on PubMed
  14. Papageorgiou A, Andreadis C, Boutis A, Lialiaris TS, Mouratidou D. NSC 290205-based therapy in murine pancreatic adenocarcinoma PAN02 in combination with adriamycin (ADR). Anticancer Res. 2006 Jan-Feb; 26(1A):243-7.
    View on PubMed
  15. Svoboda J, Andreadis C, Downs LH, Miller Jr WT, Tsai DE, Schuster SJ. Regression of advanced non-splenic marginal zone lymphoma after treatment of hepatitis C virus infection. Leuk Lymphoma. 2005 Sep; 46(9):1365-8.
    View on PubMed
  16. Chong EA, Svoboda J, Cherian S, Andreadis C, Downs LH, Zhuang H, Alavi A, Tsai DE, Schuster SJ. Regression of pulmonary MALT lymphoma after treatment with rituximab. Leuk Lymphoma. 2005 Sep; 46(9):1383-6.
    View on PubMed

Go to UCSF Profiles, powered by CTSI